Daiichi Sankyo

Daiichi Sankyo reports positive results from trial of breast cancer therapy
Daiichi Sankyo reports positive results from trial of breast cancer therapy
Clinical Trials Arena
Daiichi Sankyo
clinical trials
Dato-DXd
breast cancer
Flag link:
AstraZeneca, Daiichi Tout Phase III Breast Cancer Data in Challenge to Gilead
AstraZeneca, Daiichi Tout Phase III Breast Cancer Data in Challenge to Gilead
BioSpace
AstraZeneca
Daiichi Sankyo
breast cancer
antibody-drug conjugate
clinical trials
Flag link:
AstraZeneca, Daiichi Sankyo show off ADC portfolio with safety top of mind
AstraZeneca, Daiichi Sankyo show off ADC portfolio with safety top of mind
Fierce Biotech
AstraZeneca
Daiichi Sankyo
antibody-drug conjugate
non-small cell lung cancer
Dato-DXd
Flag link:
The 10 highest value R&D projects in biopharma
The 10 highest value R&D projects in biopharma
Fierce Biotech
R&D
biotech
Merck
sotatercept
Daiichi Sankyo
AstraZeneca
Dato-DXd
Novo Nordisk
CagriSema
Eli Lilly
donanemab
Karuna Therapeutics
Zai Lab
KarXT
Moderna Therapeutics
mRNA-1647
Novartis
iptacopan
Madrigal Pharmaceuticals
resmetirom
Cytokinetics
aficamten
Roche
Chugai
tiragolumab
Flag link:
Daiichi Sankyo to close Japanese research and development subsidiary
Daiichi Sankyo to close Japanese research and development subsidiary
Pharmaceutical Business Review
Daiichi Sankyo
Japan
R&D
RD Novare
Flag link:
Daiichi Sankyo will remain 'dominant' in ADC market for oncology treatments
Daiichi Sankyo will remain 'dominant' in ADC market for oncology treatments
Biopharma Reporter
Daiichi Sankyo
antibody drug conjugate
oncology
Seagen
Roche
Flag link:
Enhertu offers survival benefits in Phase II solid tumour trial
Enhertu offers survival benefits in Phase II solid tumour trial
Clinical Trials Arena
AstraZeneca
Daiichi Sankyo
Enhertu
clinical trials
solid tumors
Flag link:
FDA okays Daiichi Sankyo’s Vanflyta for first-line AML
FDA okays Daiichi Sankyo’s Vanflyta for first-line AML
Pharmaphorum
Daiichi Sankyo
Vanflyta
FDA
AML
Flag link:
AstraZeneca stock slides as pivotal lung cancer readout on Daiichi-partnered ADC spooks investors
AstraZeneca stock slides as pivotal lung cancer readout on Daiichi-partnered ADC spooks investors
Fierce Biotech
AstraZeneca
Daiichi Sankyo
antibody-drug conjugate
Enhertu
clinical trials
non-small cell lung cancer
Flag link:
ASCO 2023 – early first-line lung cancer data mined for datopotamab gold
ASCO 2023 – early first-line lung cancer data mined for datopotamab gold
EP Vantage
ASCO 2023
Daiichi Sankyo
AstraZeneca
datopotamab deruxtecan
non-small cell lung cancer
Flag link:
ASCO puts spotlight on advancing antibody-drug conjugate pipeline
ASCO puts spotlight on advancing antibody-drug conjugate pipeline
BioPharma Dive
ASCO 2023
antibody-drug conjugate
Merck
BioNTech
Daiichi Sankyo
Flag link:
2023’s biggest launches: the story so far
2023’s biggest launches: the story so far
EP Vantage
drug launches
AbbVie
Almirall
Apellis Pharmaceuticals
Astellas
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eli Lilly
Genmab
GSK
Iveric Bio
Pfizer
Roche
SAGE Therapeutics
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Vertex Pharmaceuticals
Flag link:
A blockbuster year could be building
A blockbuster year could be building
EP Vantage
AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Daiichi Sankyo
Eli Lilly
Gilead Sciences
Horizon Therapeutics
Merck
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
Flag link:
FDA again delays Daiichi's plans to challenge Astellas and Novartis for blood cancer market
FDA again delays Daiichi's plans to challenge Astellas and Novartis for blood cancer market
Fierce Biotech
Daiichi Sankyo
Astellas
Novartis
quizartinib
FDA
blood cancer
Flag link:
Go or no go? Seagen's Padcev eyes FDA approval
Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
FDA
AbbVie
Alvotech
Ascendis Pharma
Astellas
AstraZeneca
Biogen
Daiichi Sankyo
Eli Lilly
Ferring Pharmaceuticals
Hugel
Innoviva
Ionis Pharmaceuticals
Lundbeck
Merck
Novo Nordisk
Otsuka
Pfizer
Roche Seagen
Seres Therapeutics
Takeda
UCB
Vertex Pharmaceuticals
Flag link:
Esperion, Daiichi Sankyo milestone payment feud heats up with new lawsuit
Esperion, Daiichi Sankyo milestone payment feud heats up with new lawsuit
Fierce Pharma
Esperion Therapeutics
Daiichi Sankyo
Nexletol
SEC
Flag link:
Zymeworks, Daiichi end $293M bispecific collab after 6 unfruitful years
Zymeworks, Daiichi end $293M bispecific collab after 6 unfruitful years
Fierce Biotech
Zymeworks
Daiichi Sankyo
immuno-oncology
biobucks
Flag link:
Daiichi torches Esperion’s Nexletol milestone promises
Daiichi torches Esperion’s Nexletol milestone promises
EP Vantage
Daiichi Sankyo
Esperion Therapeutics
Nexletol
Flag link:
AstraZeneca, Daiichi Sankyo tease new Enhertu data — but details remain under wraps
AstraZeneca, Daiichi Sankyo tease new Enhertu data — but details remain under wraps
Endpoints
AstraZeneca
Daiichi Sankyo
Enhertu
clinical trials
Flag link:
Daiichi Sankyo gets US patent office to restart review of Seagen patent
Daiichi Sankyo gets US patent office to restart review of Seagen patent
Endpoints
Daiichi Sankyo
Seagen
PTO
patents
Flag link:

Pages